Skip to content

Study · Randomized controlled trial · n = 34 · 2014

8 results

Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.

Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society1 Sept 2014Cited by 140 (Europe PMC)

PMID25041740 (opens in a new tab)DOI10.1111/wrr.12211 (opens in a new tab)PepBankPUB-25041740
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In adults with hard-to-heal venous leg ulcers, topical LL‑37 raised no safety concerns for local or systemic adverse events.

    In plain wordsIn adults with leg ulcers, topical LL‑37 raised no safety concerns about local or whole-body side effects.

    Peptide
    LL-37
    Outcome
    No significant changeLocal and systemic adverse events
    Study

    n = 34

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5, 1.6 and 3.2 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no safety concerns regarding local or systemic adverse events.
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, topical LL‑37 at 0.5 mg/mL raised the healing rate constant approximately sixfold compared with placebo.

    In plain wordsIn adults with hard-to-heal leg ulcers, LL‑37 at 0.5 mg/mL made ulcers heal about six times faster than placebo.

    Peptide
    LL-37
    Outcome
    IncreaseHealing rate constant, 0.5 mg/mL versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.5 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    The healing rate constants for 0.5 and 1.6 mg/mL of LL-37 were approximately six- and threefold higher than for placebo (p = 0.003 for 0.5 mg/mL and p = 0.088 for 1.6 mg/mL).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, the healing rate constant with LL‑37 at 1.6 mg/mL was approximately threefold higher than with placebo, but this was not significant.

    In plain wordsIn adults with leg ulcers, LL‑37 at 1.6 mg/mL showed about three times faster healing than placebo, but the difference was not significant.

    Peptide
    LL-37
    Outcome
    No significant changeHealing rate constant, 1.6 mg/mL versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    1.6 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    The healing rate constants for 0.5 and 1.6 mg/mL of LL-37 were approximately six- and threefold higher than for placebo (p = 0.003 for 0.5 mg/mL and p = 0.088 for 1.6 mg/mL).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, wound area (square-root transformed) improved with LL‑37 at 0.5 mg/mL compared with pretreatment values.

    In plain wordsIn adults with leg ulcers, wounds became smaller with LL‑37 at 0.5 mg/mL compared with before treatment.

    Peptide
    LL-37
    Outcome
    DecreaseSquare-root wound area, 0.5 mg/mL versus pretreatment
    Study

    n: not reported in source

    Comparator
    Pretreatment values
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.5 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Square-root transformed wound area data showed improved healing for the 0.5 and 1.6 mg/mL dose groups compared with pretreatment values (p < 0.001 and p = 0.011, respectively).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, wound area (square-root transformed) improved with LL‑37 at 1.6 mg/mL compared with pretreatment values.

    In plain wordsIn adults with leg ulcers, wounds became smaller with LL‑37 at 1.6 mg/mL compared with before treatment.

    Peptide
    LL-37
    Outcome
    DecreaseSquare-root wound area, 1.6 mg/mL versus pretreatment
    Study

    n: not reported in source

    Comparator
    Pretreatment values
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    1.6 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Square-root transformed wound area data showed improved healing for the 0.5 and 1.6 mg/mL dose groups compared with pretreatment values (p < 0.001 and p = 0.011, respectively).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, mean ulcer area decreased by 68% in the LL‑37 0.5 mg/mL group.

    In plain wordsIn adults with leg ulcers, the average ulcer area fell by 68% with LL‑37 at 0.5 mg/mL.

    Peptide
    LL-37
    Outcome
    DecreaseMean ulcer area decrease, 0.5 mg/mL
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.5 mg/mL · topical · 4 weeksAs given in this study (human).

    Measurements

    Mean ulcer area decrease
    68%
    0.5 mg/mL

    Source sentences

    Summary
    Consistently, treatment with the two lower doses markedly decreased the mean ulcer area (68% for 0.5 mg/mL and 50% for 1.6 mg/mL groups).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, mean ulcer area decreased by 50% in the LL‑37 1.6 mg/mL group.

    In plain wordsIn adults with leg ulcers, the average ulcer area fell by 50% with LL‑37 at 1.6 mg/mL.

    Peptide
    LL-37
    Outcome
    DecreaseMean ulcer area decrease, 1.6 mg/mL
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    1.6 mg/mL · topical · 4 weeksAs given in this study (human).

    Measurements

    Mean ulcer area decrease
    50%
    1.6 mg/mL

    Source sentences

    Summary
    Consistently, treatment with the two lower doses markedly decreased the mean ulcer area (68% for 0.5 mg/mL and 50% for 1.6 mg/mL groups).
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with hard-to-heal venous leg ulcers, healing with LL‑37 at 3.2 mg/mL did not differ from placebo.

    In plain wordsIn adults with leg ulcers, LL‑37 at 3.2 mg/mL healed ulcers no differently from placebo.

    Peptide
    LL-37
    Outcome
    No significant changeHealing at 3.2 mg/mL versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    3.2 mg/mL · topical · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    No difference in healing was observed between the groups receiving 3.2 mg/mL of LL-37 and placebo.
    1 context sentence
    Summary · context
    This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.